| Name | Title | Contact Details |
|---|
Artizan Biosciences, Inc. is a biotechnology company with a mission to restore lives disrupted by inflammatory disease through innovation and advancement of microbiota-targeted therapies. We are leveraging our proprietary IgA-SEQ™ technology platform to distinguish disease-driving bacteria from the intestinal microbiota with the goal of developing new and potentially curative treatments.
Thrive Health Plans is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. Fludase is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. Paradase is an investigational nebulized drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of lower tract parainfluenza infection in immunocompromised patients.
Somaxon Pharmaceuticals, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
MabVax Therapeutics, Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.